<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Module 4: Anatomy & Treatment Sites</title>
    <style>
        :root {
            --primary: #2c3e50;
            --accent: #e74c3c; /* Red for Anatomy/Sites */
            --highlight: #f39c12;
            --bg-light: #fdfefe;
            --white: #ffffff;
        }
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            color: var(--primary);
            max-width: 900px;
            margin: 0 auto;
            padding: 20px;
            background-color: var(--bg-light);
        }
        
        /* Scaffolding Headers */
        h1 {
            text-align: center;
            color: var(--primary);
            border-bottom: 3px solid var(--accent);
            padding-bottom: 15px;
            margin-bottom: 40px;
        }
        .module-header {
            background: linear-gradient(90deg, var(--accent), var(--primary));
            color: var(--white);
            padding: 15px 20px;
            border-radius: 8px;
            margin-top: 50px;
            display: flex;
            align-items: center;
        }
        .module-number {
            background: var(--white);
            color: var(--accent);
            width: 30px;
            height: 30px;
            border-radius: 50%;
            display: inline-flex;
            align-items: center;
            justify-content: center;
            font-weight: bold;
            margin-right: 15px;
        }

        /* Content Boxes */
        .concept-block {
            background: var(--white);
            border-radius: 8px;
            padding: 25px;
            margin: 20px 0;
            box-shadow: 0 4px 6px rgba(0,0,0,0.05);
            border-left: 5px solid var(--accent);
        }
        .table-box {
            margin: 15px 0;
            overflow-x: auto;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 0.95em;
        }
        th {
            background-color: var(--accent);
            color: white;
            padding: 10px;
            text-align: left;
        }
        td {
            border: 1px solid #ddd;
            padding: 10px;
        }
        tr:nth-child(even) {background-color: #fff9f9;}

        /* "Watch Out" Tips */
        .watch-out {
            background-color: #fff5f5;
            border: 1px solid #ffcccc;
            border-radius: 5px;
            padding: 15px;
            margin-top: 15px;
            font-size: 0.9em;
        }
        .watch-out strong {
            color: #c0392b;
            text-transform: uppercase;
            font-size: 0.85em;
            letter-spacing: 1px;
        }

        /* Graphics Container */
        .visual-aid {
            text-align: center;
            margin: 20px 0;
            background: var(--white);
            padding: 20px;
            border-radius: 8px;
            border: 1px solid #eee;
        }
    </style>
</head>
<body>

    <h1>Module 4: Anatomy, Landmarks & Critical Structures</h1>
    <p style="text-align: center; font-size: 1.1em;">
        Focusing on Field Borders, Lymphatic Drainage, and Dose Limits (TD 5/5).
    </p>

    <div class="module-header">
        <span class="module-number">1</span>
        <h2>Dose Limiting Structures (TD 5/5)</h2>
    </div>
    <p>You must memorize these values. Exceeding them causes irreversible damage.</p>

    <div class="concept-block">
        <h3>1.1 The "Do Not Exceed" List</h3>
        <div class="table-box">
            <table>
                <tr>
                    <th>Organ</th>
                    <th>TD 5/5 (Gy)</th>
                    <th>Endpoint (Effect)</th>
                </tr>
                <tr>
                    <td><strong>Spinal Cord</strong></td>
                    <td><strong>45 - 50 Gy</strong></td>
                    <td>Myelitis / Necrosis (Paralysis)</td>
                </tr>
                <tr>
                    <td><strong>Brain Stem</strong></td>
                    <td>50 Gy</td>
                    <td>Necrosis / Nerve Palsy</td>
                </tr>
                <tr>
                    <td><strong>Optic Chiasm</strong></td>
                    <td>50 Gy</td>
                    <td>Blindness</td>
                </tr>
                <tr>
                    <td><strong>Lens of Eye</strong></td>
                    <td><strong>10 Gy</strong></td>
                    <td>Cataracts</td>
                </tr>
                <tr>
                    <td><strong>Lung</strong></td>
                    <td>17.5 Gy</td>
                    <td>Pneumonitis</td>
                </tr>
                <tr>
                    <td><strong>Parotid Gland</strong></td>
                    <td>32 Gy</td>
                    <td>Xerostomia (Dry Mouth)</td>
                </tr>
                <tr>
                    <td><strong>Kidney</strong></td>
                    <td>23 Gy</td>
                    <td>Nephritis</td>
                </tr>
                <tr>
                    <td><strong>Liver</strong></td>
                    <td>30 Gy</td>
                    <td>Liver Failure</td>
                </tr>
                <tr>
                    <td><strong>Small Bowel</strong></td>
                    <td>40 Gy</td>
                    <td>Obstruction / Perforation</td>
                </tr>
                <tr>
                    <td><strong>Heart</strong></td>
                    <td>40 Gy</td>
                    <td>Pericarditis</td>
                </tr>
            </table>
        </div>
        <div class="watch-out">
            <strong>Exam Strategy:</strong> The exam often asks about "Parallel" vs. "Serial" organs.
            <ul>
                <li><strong>Serial (Spine):</strong> Damage to ONE part disables the WHOLE organ. (Max dose matters).</li>
                <li><strong>Parallel (Lung, Liver):</strong> Damage to one part is okay; the rest can function. (Mean dose / Volume matters).</li>
            </ul>
        </div>
    </div>

    <div class="module-header">
        <span class="module-number">2</span>
        <h2>Classic Field Borders</h2>
    </div>
    <p>Localization scores dropped (8.2 -> 6.5). Recover points here by knowing exactly where the field edges land.</p>

    <div class="concept-block">
        <h3>2.1 Whole Brain (WB) Borders</h3>
        <div class="visual-aid">
            
            <svg width="300" height="200" viewBox="0 0 300 200">
                <path d="M 50 150 Q 50 50 150 50 Q 250 50 250 150 L 250 180 L 50 180 Z" fill="#ecf0f1" stroke="#333"/>
                <circle cx="230" cy="110" r="5" fill="#333"/>
                <ellipse cx="150" cy="130" rx="5" ry="10" fill="none" stroke="#333"/>
                
                <line x1="240" y1="110" x2="140" y2="170" stroke="#e74c3c" stroke-width="2" stroke-dasharray="5"/>
                <text x="180" y="100" font-size="10" fill="#e74c3c">Inferior Border</text>
            </svg>
        </div>
        <ul>
            <li><strong>Superior:</strong> Clear of cranium (1 cm "flash" or shine-over).</li>
            <li><strong>Inferior:</strong> From the <strong>Supra-Orbital Ridge</strong> (Intersection of outer canthus) to the <strong>Mastoid Tip</strong> (or EAM).</li>
            <li><strong>Anterior:</strong> Clear of cranium (flash).</li>
            <li><strong>Posterior:</strong> Clear of cranium (flash).</li>
        </ul>
        <div class="watch-out">
            <strong>Block Checklist:</strong> You MUST block the <strong>Lens of the Eye</strong>. You usually block the anterior face (sinuses) to spare healthy tissue.
        </div>
    </div>

    <div class="concept-block">
        <h3>2.2 Spine Fields</h3>
        <ul>
            <li><strong>Width:</strong> Typically 6-8 cm wide (enough to cover vertebral body + transverse processes).</li>
            <li><strong>Length:</strong> Must cover the lesion + 1 vertebral body above and 1 below (margin).</li>
        </ul>
        <p><strong>Landmarks for Spine Level:</strong></p>
        <div class="table-box">
            <table>
                <tr>
                    <th>Vertebra</th>
                    <th>Anatomical Landmark</th>
                </tr>
                <tr>
                    <td><strong>C1</strong></td>
                    <td>Mastoid Tip</td>
                </tr>
                <tr>
                    <td><strong>C4</strong></td>
                    <td>Hyoid Bone</td>
                </tr>
                <tr>
                    <td><strong>T2</strong></td>
                    <td>SSN (Suprasternal Notch)</td>
                </tr>
                <tr>
                    <td><strong>T4</strong></td>
                    <td>Angle of Louis (Carina)</td>
                </tr>
                <tr>
                    <td><strong>T10</strong></td>
                    <td>Xiphoid Process</td>
                </tr>
                <tr>
                    <td><strong>L4</strong></td>
                    <td>Iliac Crest</td>
                </tr>
            </table>
        </div>
    </div>

    <div class="module-header">
        <span class="module-number">3</span>
        <h2>Treatment Sites & Lymphatics</h2>
    </div>

    <div class="concept-block">
        <h3>3.1 Breast Cancer</h3>
        <p><strong>Standard Fields:</strong> Tangents (Medial & Lateral). Occasionally Supraclavicular (SCV) and Posterior Axillary Boost (PAB).</p>
        <ul>
            <li><strong>Borders:</strong>
                <ul>
                    <li><em>Medial:</em> Midline (SSN to Xiphoid).</li>
                    <li><em>Lateral:</em> Mid-Axillary Line (2cm beyond breast tissue).</li>
                    <li><em>Superior:</em> First intercostal space (Head of Clavicle).</li>
                    <li><em>Inferior:</em> 1.5 cm below inframammary fold.</li>
                </ul>
            </li>
            <li><strong>Lymphatics:</strong> Primary drainage is <strong>Axillary Level I, II, III</strong>. Inner quadrant tumors may drain to <strong>Internal Mammary</strong> nodes.</li>
        </ul>
    </div>

    <div class="concept-block">
        <h3>3.2 Prostate Cancer</h3>
        <p><strong>Simulation Instructions:</strong>
            <ul>
                <li><strong>Full Bladder:</strong> Pushes the small bowel <em>up and out</em> of the treatment field (spares bowel).</li>
                <li><strong>Empty Rectum:</strong> Maintains consistent prostate position (reduces motion).</li>
            </ul>
        </p>
        <p><strong>Lymphatics:</strong> Obturator nodes, Internal Iliac nodes, External Iliac nodes.</p>
    </div>

    <div class="module-header">
        <span class="module-number">4</span>
        <h2>Oncologic Emergencies</h2>
    </div>
    <p>These patients are treated STAT. You must know the symptoms and typical fractionation.</p>

    <div class="concept-block">
        <h3>4.1 SVC Syndrome (Superior Vena Cava)</h3>
        <ul>
            <li><strong>Cause:</strong> Lung mass compressing the SVC.</li>
            <li><strong>Symptoms:</strong> Facial edema (swelling), Dyspnea (trouble breathing), Venous distention in neck.</li>
            <li><strong>Treatment:</strong> Radiation immediately. Usually high dose per fraction initially (e.g., 300-400 cGy) to shrink tumor fast.</li>
        </ul>
    </div>

    <div class="concept-block">
        <h3>4.2 Spinal Cord Compression</h3>
        <ul>
            <li><strong>Cause:</strong> Tumor pressing on the cord.</li>
            <li><strong>Symptoms:</strong> Pain, weakness, loss of bladder/bowel control.</li>
            <li><strong>Treatment:</strong> Steroids + Radiation immediately to prevent permanent paralysis.</li>
        </ul>
    </div>
    <style>
        :root {
            --header-bg: #2c3e50;
            --header-text: #ffffff;
            --accent: #3498db;
            --row-light: #fdfdfd;
            --row-dark: #f4f6f7;
            --border: #bdc3c7;
        }
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.5;
            color: #333;
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
            background-color: #ecf0f1;
        }
        h1 {
            text-align: center;
            color: var(--header-bg);
            border-bottom: 4px solid var(--accent);
            padding-bottom: 10px;
            margin-bottom: 30px;
        }
        h2 {
            background-color: var(--accent);
            color: white;
            padding: 10px 15px;
            border-radius: 5px;
            margin-top: 40px;
            font-size: 1.5em;
        }
        
        /* Table Styling */
        table {
            width: 100%;
            border-collapse: collapse;
            background-color: white;
            box-shadow: 0 2px 5px rgba(0,0,0,0.1);
            margin-bottom: 30px;
        }
        th {
            background-color: var(--header-bg);
            color: var(--header-text);
            text-align: left;
            padding: 12px;
            width: 25%;
            border-bottom: 1px solid var(--border);
            vertical-align: top;
        }
        td {
            padding: 12px;
            border-bottom: 1px solid #eee;
            vertical-align: top;
        }
        tr:nth-child(even) {
            background-color: var(--row-dark);
        }
        
        /* Specific Tags */
        .dose-tag {
            font-weight: bold;
            color: #c0392b;
            background: #fadbd8;
            padding: 2px 6px;
            border-radius: 4px;
            font-size: 0.9em;
        }
        .border-tag {
            font-weight: bold;
            color: #2980b9;
        }
        .path-tag {
            font-style: italic;
            color: #27ae60;
            font-weight: bold;
        }
        
        /* SVG Centering */
        .graphic-container {
            text-align: center;
            margin: 10px 0;
            padding: 10px;
            background: #fff;
            border: 1px dashed #ccc;
        }
    </style>
</head>
<body>

    <h1>Module 4: Master Site-Specific Oncology Review</h1>
    <a id="cns"></a>
    <h2>1. Central Nervous System (Brain & Spinal Cord)</h2>
    <table>
        <tr>
            <th>Anatomy & Lymphatics</th>
            <td>
                <ul>
                    <li><strong>Anatomy:</strong> Cerebrum (adult tumors), Cerebellum/Brainstem (pediatric tumors). No lymphatic drainage in the brain (Blood-Brain Barrier).</li>
                    <li><strong>CSF Flow:</strong> Ventricles â†’ Spinal Cord. Important for Medulloblastoma spread (Drop Mets).</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Epidemiology & Etiology</th>
            <td>
                <ul>
                    <li><strong>Most Common (Adult):</strong> Metastatic lesions (from Lung/Breast).</li>
                    <li><strong>Most Common (Primary Adult):</strong> Glioblastoma Multiforme (GBM).</li>
                    <li><strong>Most Common (Child):</strong> Medulloblastoma / Astrocytoma.</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Pathology (Histology & Grading)</th>
            <td>
                <ul>
                    <li><strong>Type:</strong> <span class="path-tag">Gliomas</span> (Astrocytes), Medulloblastoma (PNET), Meningioma (Benign).</li>
                    <li><strong>Grading:</strong> G1 (Benign) to G4 (GBM - highly necrotic/aggressive).</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Clinical Presentation</th>
            <td>Headache (worse in morning), Seizures, Nausea/Vomiting (ICP), Personality changes (Frontal lobe), Vision changes.</td>
        </tr>
        <tr>
            <th>Radiation Specifics<br>(Borders & Techniques)</th>
            <td>
                <strong>Whole Brain Fields (Metastasis):</strong>
                <ul>
                    <li><span class="border-tag">Inferior:</span> Supra-orbital ridge to Mastoid Tip (or EAM).</li>
                    <li><span class="border-tag">Flash:</span> 1-2 cm flash on Anterior, Superior, Posterior.</li>
                    <li><strong>Blocks:</strong> Eye Blocks (Lens).</li>
                </ul>
                <strong>Craniospinal (CSI) for Medulloblastoma:</strong>
                <ul>
                    <li>Must treat entire brain and spine. Junction shifts (feathering) required to prevent hot/cold spots at cord.</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Doses & OARs</th>
            <td>
                <ul>
                    <li><strong>Whole Brain:</strong> 30 Gy / 10 fx OR 37.5 Gy / 15 fx.</li>
                    <li><strong>Primary GBM:</strong> 60 Gy Total (45-50 Gy Initial + Boost).</li>
                    <li><strong>OARs:</strong> <span class="dose-tag">Lens: 10 Gy</span> (Cataracts), <span class="dose-tag">Optic Chiasm: 50 Gy</span> (Blindness), <span class="dose-tag">Brainstem: 50 Gy</span>.</li>
                </ul>
            </td>
        </tr>
    </table>

    <a id="hn"></a>
    <h2>2. Head & Neck (Larynx, Oral Cavity, Pharynx)</h2>
    <table>
        <tr>
            <th>Anatomy & Lymphatics</th>
            <td>
                <div class="graphic-container">
                    
                    <svg width="200" height="150" viewBox="0 0 200 150">
                        <path d="M 50 20 Q 150 20 150 130" stroke="#333" fill="none"/>
                        <circle cx="90" cy="40" r="8" fill="#e74c3c" opacity="0.5"/><text x="85" y="45" font-size="10">II</text>
                        <circle cx="90" cy="70" r="8" fill="#e74c3c" opacity="0.5"/><text x="85" y="75" font-size="10">III</text>
                        <circle cx="90" cy="100" r="8" fill="#e74c3c" opacity="0.5"/><text x="85" y="105" font-size="10">IV</text>
                        <text x="10" y="10" font-size="10" fill="#555">Jugulodigastric Chain</text>
                    </svg>
                </div>
                <ul>
                    <li><strong>Lymph Nodes:</strong> Levels I-V (Submental to Supraclav). Rouviere's Node (Retropharyngeal) is crucial for Nasopharynx.</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Epidemiology & Etiology</th>
            <td>
                <ul>
                    <li><strong>Risk Factors:</strong> Smoking + Alcohol (Synergistic effect). EBV (Nasopharynx). HPV (Oropharynx/Base of Tongue).</li>
                    <li><strong>Gender:</strong> More common in males (historically).</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Pathology (Histology)</th>
            <td>
                <ul>
                    <li><strong>Majority (80%):</strong> <span class="path-tag">Squamous Cell Carcinoma (SCC)</span>.</li>
                    <li><strong>Exception:</strong> Salivary Glands = <span class="path-tag">Adenocarcinoma</span>.</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Radiation Specifics<br>(Borders & Techniques)</th>
            <td>
                <strong>True Vocal Cord (Glottic Larynx):</strong> Small fields (5x5 or 6x6).
                <ul>
                    <li><span class="border-tag">Superior:</span> Top of Thyroid Cartilage.</li>
                    <li><span class="border-tag">Inferior:</span> Cricoid Cartilage.</li>
                    <li><span class="border-tag">Anterior:</span> 1.5 cm Flash ("Shine over").</li>
                    <li><span class="border-tag">Posterior:</span> Anterior to Vertebral Body (exclude spine).</li>
                </ul>
                <strong>Whole Neck (IMRT/VMAT):</strong> Treats primary + bilateral nodes.
            </td>
        </tr>
        <tr>
            <th>Doses & OARs</th>
            <td>
                <ul>
                    <li><strong>Curative Dose:</strong> 70 Gy (2 Gy/fx).</li>
                    <li><strong>Lymphoma (Waldeyer's Ring):</strong> Lower dose (30-40 Gy).</li>
                    <li><strong>OARs:</strong> <span class="dose-tag">Spinal Cord: 45 Gy</span>, <span class="dose-tag">Parotid: 32 Gy</span> (Xerostomia/Dry Mouth).</li>
                </ul>
            </td>
        </tr>
    </table>

    <a id="breast"></a>
    <h2>3. Breast Cancer</h2>
    <table>
        <tr>
            <th>Anatomy & Lymphatics</th>
            <td>
                <ul>
                    <li><strong>Nodes:</strong> Axillary Levels I, II, III. Internal Mammary Chain (medial tumors). Supraclavicular nodes.</li>
                    <li><strong>Location:</strong> Upper Outer Quadrant (UOQ) / Tail of Spence is most common (50%).</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Pathology (Histology)</th>
            <td>
                <ul>
                    <li><strong>Most Common:</strong> <span class="path-tag">Infiltrating Ductal Carcinoma (IDC)</span> (~80%).</li>
                    <li><strong>Others:</strong> Lobular Carcinoma (LCIS/ILC), Inflammatory (Aggressive/Peau d'orange).</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Radiation Specifics<br>(Borders & Techniques)</th>
            <td>
                <strong>Tangential Fields (Chest Wall/Breast):</strong>
                <ul>
                    <li><span class="border-tag">Medial:</span> Midline (SSN to Xiphoid).</li>
                    <li><span class="border-tag">Lateral:</span> Mid-Axillary Line (2 cm beyond breast tissue).</li>
                    <li><span class="border-tag">Superior:</span> First Intercostal Space / Head of Clavicle.</li>
                    <li><span class="border-tag">Inferior:</span> 1.5 cm below Inframammary Fold.</li>
                </ul>
                <strong>Technique:</strong> Deep Inspiration Breath Hold (DIBH) used for Left Breast to spare Heart.
            </td>
        </tr>
        <tr>
            <th>Doses & OARs</th>
            <td>
                <ul>
                    <li><strong>Whole Breast:</strong> 45-50 Gy (or Hypofractionated 42.5 Gy / 16 fx).</li>
                    <li><strong>Boost (Lumpectomy Bed):</strong> +10-16 Gy electrons/photons. Total ~60-66 Gy.</li>
                    <li><strong>OARs:</strong> <span class="dose-tag">Lung: 17.5 Gy</span> (Pneumonitis), <span class="dose-tag">Heart: 40 Gy</span> (Pericarditis/Late Cardiac).</li>
                </ul>
            </td>
        </tr>
    </table>

    <a id="lung"></a>
    <h2>4. Lung / Thorax</h2>
    <table>
        <tr>
            <th>Epidemiology & Pathology</th>
            <td>
                <ul>
                    <li><strong>Non-Small Cell (NSCLC):</strong> 80%. Includes <span class="path-tag">Adenocarcinoma</span> (Periphery, Non-smokers) and <span class="path-tag">Squamous Cell</span> (Central, Smokers).</li>
                    <li><strong>Small Cell (SCLC):</strong> 20%. Central. Very aggressive. High met rate to Brain. "Oat Cell".</li>
                    <li><strong>Mesothelioma:</strong> Asbestos exposure. Pleura lining.</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Clinical Presentation</th>
            <td>Cough, Hemoptysis (bloody sputum), Dyspnea.
                <br><strong>Pancoast Tumor:</strong> Apex of lung. Causes Horner's Syndrome (Ptosis, Miosis, Anhidrosis) and Arm Pain.
                <br><strong>SVC Syndrome:</strong> Facial swelling, distended neck veins (Emergency).</td>
        </tr>
        <tr>
            <th>Radiation Specifics<br>(Techniques)</th>
            <td>
                <ul>
                    <li><strong>Motion Management:</strong> 4D CT (Respiratory Gating) or Compression required due to breathing motion.</li>
                    <li><strong>SBRT:</strong> Used for early stage/small lesions. Very high dose, few fractions (e.g., 54 Gy / 3 fx).</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Doses & OARs</th>
            <td>
                <ul>
                    <li><strong>Definitive Dose:</strong> 60-66 Gy.</li>
                    <li><strong>Palliative:</strong> 30 Gy / 10 fx.</li>
                    <li><strong>OARs:</strong> <span class="dose-tag">Spinal Cord: 45 Gy</span>, <span class="dose-tag">Heart: 40 Gy</span>, <span class="dose-tag">Lung (V20):</span> Minimize volume receiving 20 Gy.</li>
                </ul>
            </td>
        </tr>
    </table>

    <a id="gi"></a>
    <h2>5. Gastrointestinal (Esophagus, Pancreas, Rectum)</h2>
    <table>
        <tr>
            <th>Pathology (Histology)</th>
            <td>
                <ul>
                    <li><strong>Esophagus:</strong> Upper = Squamous. Lower/Distal = Adenocarcinoma (Barrett's Esophagus/GERD).</li>
                    <li><strong>Pancreas:</strong> <span class="path-tag">Adenocarcinoma</span> (Head of Pancreas). Jaundice is key symptom.</li>
                    <li><strong>Rectum/Colon:</strong> <span class="path-tag">Adenocarcinoma</span>.</li>
                    <li><strong>Anal Canal:</strong> <span class="path-tag">Squamous Cell</span> (HPV linked).</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Radiation Specifics<br>(Techniques)</th>
            <td>
                <ul>
                    <li><strong>Rectum:</strong> Prone position often used with "Belly Board" to displace small bowel out of field. Full bladder also pushes bowel up.</li>
                    <li><strong>Anal Canal:</strong> "Nigro Protocol" (Chemo + Rad). Sphincter preservation is the goal. Inguinal nodes must be treated.</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Doses & OARs</th>
            <td>
                <ul>
                    <li><strong>GI Standard Dose:</strong> 45-50.4 Gy. (Limited by small bowel tolerance).</li>
                    <li><strong>OARs:</strong> <span class="dose-tag">Small Bowel: 40-45 Gy</span> (Obstruction/Perforation), <span class="dose-tag">Liver: 30 Gy</span>, <span class="dose-tag">Kidneys: 23 Gy</span>.</li>
                </ul>
            </td>
        </tr>
    </table>

    <a id="gu"></a>
    <h2>6. Genitourinary (Prostate, Bladder, Testis)</h2>
    <table>
        <tr>
            <th>Pathology (Histology)</th>
            <td>
                <ul>
                    <li><strong>Prostate:</strong> <span class="path-tag">Adenocarcinoma</span>. Gleason Score used for Grading.</li>
                    <li><strong>Bladder:</strong> <span class="path-tag">Transitional Cell Carcinoma (TCC)</span>. Linked to smoking/industrial chemicals.</li>
                    <li><strong>Testicular:</strong> <span class="path-tag">Seminoma</span> (Germ Cell). Radiosensitive.</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Radiation Specifics<br>(Techniques)</th>
            <td>
                <strong>Prostate Sim:</strong>
                <ul>
                    <li><span class="border-tag">Full Bladder:</span> Pushes small bowel up/out.</li>
                    <li><span class="border-tag">Empty Rectum:</span> Reproducibility.</li>
                </ul>
                <strong>Testicular (Seminoma):</strong> Treat "Hockey Stick" or "Dog Leg" field (Para-aortic + Ipsilateral Iliac nodes).
            </td>
        </tr>
        <tr>
            <th>Doses & OARs</th>
            <td>
                <ul>
                    <li><strong>Prostate:</strong> Escalated dose 75-80 Gy (IMRT/VMAT).</li>
                    <li><strong>Seminoma:</strong> Low dose ~25-30 Gy.</li>
                    <li><strong>OARs:</strong> <span class="dose-tag">Rectum: 60 Gy</span> (Bleeding/Fistula), <span class="dose-tag">Bladder: 65 Gy</span>, <span class="dose-tag">Femoral Heads: 52 Gy</span>.</li>
                </ul>
            </td>
        </tr>
    </table>

    <a id="gyn"></a>
    <h2>7. Gynecological (Cervix, Endometrium)</h2>
    <table>
        <tr>
            <th>Pathology (Histology)</th>
            <td>
                <ul>
                    <li><strong>Cervix:</strong> <span class="path-tag">Squamous Cell Carcinoma</span>. HPV association.</li>
                    <li><strong>Endometrium (Uterus):</strong> <span class="path-tag">Adenocarcinoma</span>. Hormonal/Obesity link. Most common GYN cancer.</li>
                    <li><strong>Ovarian:</strong> Epithelial. Spreads via seeding (peritoneal fluid). "Silent Killer".</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Radiation Specifics<br>(Techniques)</th>
            <td>
                <strong>Brachytherapy (Internal):</strong> Critical for Cervix.
                <ul>
                    <li><strong>Point A:</strong> 2 cm superior to cervical os, 2 cm lateral. Represents medial parametrium/ureter crossing.</li>
                    <li><strong>Point B:</strong> 3 cm lateral to Point A (Pelvic wall nodes).</li>
                    <li><strong>Tandem & Ovoids:</strong> Common applicators.</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Doses</th>
            <td>
                <ul>
                    <li><strong>External Beam:</strong> 45 Gy to Whole Pelvis ("4-Field Box").</li>
                    <li><strong>Brachytherapy Boost:</strong> brings total dose to cervix >80 Gy.</li>
                </ul>
            </td>
        </tr>
    </table>

    <a id="lymph"></a>
    <h2>8. Lymphoma & Sarcoma</h2>
    <table>
        <tr>
            <th>Pathology (Histology)</th>
            <td>
                <ul>
                    <li><strong>Hodgkin's (HL):</strong> Presence of <span class="path-tag">Reed-Sternberg Cell</span>. Contiguous spread (predictable). Bimodal age peaks.</li>
                    <li><strong>Non-Hodgkin's (NHL):</strong> Diffuse spread. No Reed-Sternberg. B-Cell or T-Cell.</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Radiation Specifics<br>(Fields)</th>
            <td>
                <ul>
                    <li><strong>Mantle Field (Historical):</strong> Large field covering neck, axilla, mediastinum. Blocked lungs/humeral heads.</li>
                    <li><strong>Inverted Y:</strong> Covers para-aortic and pelvic nodes.</li>
                    <li><strong>Current Standard:</strong> Involved Site Radiation Therapy (ISRT) - smaller, tighter margins.</li>
                </ul>
            </td>
        </tr>
        <tr>
            <th>Doses</th>
            <td>
                <ul>
                    <li><strong>Lymphoma:</strong> Very radiosensitive. 30-36 Gy.</li>
                    <li><strong>Sarcoma (Soft Tissue):</strong> Radioresistant. Requires 60-66 Gy post-op. Strip of tissue spared to prevent lymphedema.</li>
                </ul>
            </td>
        </tr>
    </table>

</body>
</html>
